Thomas CS Martin T, Laramie R Smith, Christy Anderson, Susan J Little
{"title":"采用快速抗逆转录病毒疗法的 \"60 分钟促进健康 \"随机对照试验,帮助脱离护理的艾滋病毒感染者重新融入社会","authors":"Thomas CS Martin T, Laramie R Smith, Christy Anderson, Susan J Little","doi":"10.1097/qai.0000000000003460","DOIUrl":null,"url":null,"abstract":"\n \n Many persons with HIV remain out of care (PWH-OOC). We evaluated InstaCare, a complex intervention integrating the brief behavioral intervention 60-Minutes-for-Health with rapid re-start of antiretroviral therapy (rapid-ART).\n \n \n \n Prospective open-label randomized controlled trial among PWH-OOC in San Diego, USA\n \n \n \n PWH-OOC were randomized 1:1 to InstaCare or a time-and-attention control integrating a diet-and-nutrition behavioral intervention also with rapid-ART initiation (restart ≤7 days from enrolment). All participants had access to support services (free transport, HIV peer-navigation, adherence counseling and linkage to care) and primary care services (mental health, case management, social work, medication assisted treatment, and specialist pharmacy). The primary outcomes were viral suppression (<50 copies/ml) and re-engagement with care (≥2 HIV care visits >90 days apart) by 24 weeks. Outcomes were reported on an intention-to-treat basis.\n \n \n \n Between November 2020 and August 2022, 52 PWH-OOC were enrolled. Baseline substance use in the preceding month (49%), unstable housing (51%), moderate/severe depression (49%), and moderate/severe anxiety (41.7%) were prevalent. Rapid-ART was provided for all participants. At week 24, the proportion with HIV viral load <50 copies/ml was 37.3% (19/51) (InstaCare 28.0%, control 46.2%, p=0.25). Fourteen (27.5%) were engaged with care (InstaCare 7/25 [28.0%], control 7/26 [26.9%], p=1.00). Most participants (94%) reported low or very low emotional distress associated with rapid-ART. Study lost to follow-up by week 24 was high (23/51, 45%).\n \n \n \n The InstaCare complex intervention did not improve viral suppression or re-engagement with care among PWH-OOC. Investigation of high-intensity, individually-adapted interventions are needed among PWH-OOC.\n","PeriodicalId":14588,"journal":{"name":"JAIDS Journal of Acquired Immune Deficiency Syndromes","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Randomized controlled trial of 60-Minutes-for-Health with rapid antiretroviral therapy to re-engage persons with HIV who are out of care\",\"authors\":\"Thomas CS Martin T, Laramie R Smith, Christy Anderson, Susan J Little\",\"doi\":\"10.1097/qai.0000000000003460\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\\n \\n Many persons with HIV remain out of care (PWH-OOC). We evaluated InstaCare, a complex intervention integrating the brief behavioral intervention 60-Minutes-for-Health with rapid re-start of antiretroviral therapy (rapid-ART).\\n \\n \\n \\n Prospective open-label randomized controlled trial among PWH-OOC in San Diego, USA\\n \\n \\n \\n PWH-OOC were randomized 1:1 to InstaCare or a time-and-attention control integrating a diet-and-nutrition behavioral intervention also with rapid-ART initiation (restart ≤7 days from enrolment). All participants had access to support services (free transport, HIV peer-navigation, adherence counseling and linkage to care) and primary care services (mental health, case management, social work, medication assisted treatment, and specialist pharmacy). The primary outcomes were viral suppression (<50 copies/ml) and re-engagement with care (≥2 HIV care visits >90 days apart) by 24 weeks. Outcomes were reported on an intention-to-treat basis.\\n \\n \\n \\n Between November 2020 and August 2022, 52 PWH-OOC were enrolled. Baseline substance use in the preceding month (49%), unstable housing (51%), moderate/severe depression (49%), and moderate/severe anxiety (41.7%) were prevalent. Rapid-ART was provided for all participants. At week 24, the proportion with HIV viral load <50 copies/ml was 37.3% (19/51) (InstaCare 28.0%, control 46.2%, p=0.25). Fourteen (27.5%) were engaged with care (InstaCare 7/25 [28.0%], control 7/26 [26.9%], p=1.00). Most participants (94%) reported low or very low emotional distress associated with rapid-ART. Study lost to follow-up by week 24 was high (23/51, 45%).\\n \\n \\n \\n The InstaCare complex intervention did not improve viral suppression or re-engagement with care among PWH-OOC. Investigation of high-intensity, individually-adapted interventions are needed among PWH-OOC.\\n\",\"PeriodicalId\":14588,\"journal\":{\"name\":\"JAIDS Journal of Acquired Immune Deficiency Syndromes\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.9000,\"publicationDate\":\"2024-05-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JAIDS Journal of Acquired Immune Deficiency Syndromes\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/qai.0000000000003460\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JAIDS Journal of Acquired Immune Deficiency Syndromes","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/qai.0000000000003460","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
Randomized controlled trial of 60-Minutes-for-Health with rapid antiretroviral therapy to re-engage persons with HIV who are out of care
Many persons with HIV remain out of care (PWH-OOC). We evaluated InstaCare, a complex intervention integrating the brief behavioral intervention 60-Minutes-for-Health with rapid re-start of antiretroviral therapy (rapid-ART).
Prospective open-label randomized controlled trial among PWH-OOC in San Diego, USA
PWH-OOC were randomized 1:1 to InstaCare or a time-and-attention control integrating a diet-and-nutrition behavioral intervention also with rapid-ART initiation (restart ≤7 days from enrolment). All participants had access to support services (free transport, HIV peer-navigation, adherence counseling and linkage to care) and primary care services (mental health, case management, social work, medication assisted treatment, and specialist pharmacy). The primary outcomes were viral suppression (<50 copies/ml) and re-engagement with care (≥2 HIV care visits >90 days apart) by 24 weeks. Outcomes were reported on an intention-to-treat basis.
Between November 2020 and August 2022, 52 PWH-OOC were enrolled. Baseline substance use in the preceding month (49%), unstable housing (51%), moderate/severe depression (49%), and moderate/severe anxiety (41.7%) were prevalent. Rapid-ART was provided for all participants. At week 24, the proportion with HIV viral load <50 copies/ml was 37.3% (19/51) (InstaCare 28.0%, control 46.2%, p=0.25). Fourteen (27.5%) were engaged with care (InstaCare 7/25 [28.0%], control 7/26 [26.9%], p=1.00). Most participants (94%) reported low or very low emotional distress associated with rapid-ART. Study lost to follow-up by week 24 was high (23/51, 45%).
The InstaCare complex intervention did not improve viral suppression or re-engagement with care among PWH-OOC. Investigation of high-intensity, individually-adapted interventions are needed among PWH-OOC.
期刊介绍:
JAIDS: Journal of Acquired Immune Deficiency Syndromes seeks to end the HIV epidemic by presenting important new science across all disciplines that advance our understanding of the biology, treatment and prevention of HIV infection worldwide.
JAIDS: Journal of Acquired Immune Deficiency Syndromes is the trusted, interdisciplinary resource for HIV- and AIDS-related information with a strong focus on basic and translational science, clinical science, and epidemiology and prevention. Co-edited by the foremost leaders in clinical virology, molecular biology, and epidemiology, JAIDS publishes vital information on the advances in diagnosis and treatment of HIV infections, as well as the latest research in the development of therapeutics and vaccine approaches. This ground-breaking journal brings together rigorously peer-reviewed articles, reviews of current research, results of clinical trials, and epidemiologic reports from around the world.